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Programmed cell death protein (PD-1) and its ligands play a fundamental role in the
evasion of tumor cells from antitumor immunity. Less well appreciated is the fact that the
PD-1/PD-L1 axis also regulates antiviral immune responses and is therefore modulated
by a number of viruses. Upregulation of PD-1 and its ligands PD-L1 and PD-L2 is
observed during acute virus infection and after infection with persistent viruses including
important human pathogens such as human immunodeficiency virus (HIV), hepatitis C
virus (HCV), and hepatitis B virus (HBV). Experimental evidence suggests that insufficient
signaling through the PD-1 pathway promotes immunopathology during acute infection
by exaggerating primary T cell responses. If chronic infection is established, however,
high levels of PD-1 expression can have unfavorable immunological consequences.
Exhaustion and suppression of antiviral immune responses can result in viral immune
evasion. The role of the PD-1/PD-L1 axis during viral infections is further complicated
by evidence that PD-L1 also mediates inflammatory effects in the acute phase of an
immune response. In this review, we discuss the intricate interplay between viruses and
the PD-1/PD-L1 axis.
Keywords: PD-1, PD-L1, PD-L2, antiviral immune responses, viral immune evasion, virus-induced
immunopathogenesis, viruses
INTRODUCTION
Programmed cell death 1 (PD-1, also known as CD279) was discovered by Tasuku Honjo et al. at
Kyoto University from a screen of genes involved in programmed cell death (Ishida et al., 1992).
PD-1 expression is rapidly induced after signaling through the T cell receptor (TCR) andmodulated
by cytokines (Agata et al., 1996; Yamazaki et al., 2002; Wherry et al., 2007; Chikuma et al., 2009;
Terawaki et al., 2011; Ahn et al., 2018). Other types of immune cells such as B cells, natural killer
(NK) cells, NKT cells, dendritic cells (DCs), and monocytes also express PD-1 (Sharpe et al., 2007;
Keir et al., 2008).
There is ample evidence that PD-1, a member of the immunoglobulin superfamily, regulates
the magnitude and quality of T cell responses. It plays a pivotal role in the induction and
maintenance of central as well as peripheral tolerance (Nishimura et al., 1999, 2001; Wang et al.,
2005; Okazaki andHonjo, 2006; Francisco et al., 2010; Fife and Pauken, 2011). For example, antigen
presentation by resting DCs induces peripheral CD8+ T cell tolerance by signaling through PD-
1 on CD8+ T cells (Probst et al., 2005). In fact, PD-1 has been called a ‘rheostat’ that calibrates
threshold, strength, and duration of T cell responses (Okazaki et al., 2013; Honda et al., 2014).
PD-1 belongs to a group of structurally different surface molecules that function as co-inhibitory
receptors during immune responses against pathogens and cancer (Attanasio and Wherry, 2016;
Hashimoto et al., 2018; Sharpe and Pauken, 2018). These molecules counterbalance co-stimulatory
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receptors on T cells such as CD28, which bind to CD80
and CD86 on professional APCs and facilitate T cell
activation (Esensten et al., 2016).
Clinical studies have shown that blocking the PD-1 pathway
is effective against several types of cancer including melanoma,
lymphoma, lung, and renal cancer (Sanmamed and Chen, 2018).
This type of treatment is referred to as immune checkpoint
therapy and the blocking reagents are called immune checkpoint-
inhibitors (ICIs). Together with James P. Allison, who worked
on another co-inhibitory receptor called cytotoxic T-lymphocyte-
associated Protein 4 (CTLA-4), Tasuku Honjo was awarded the
Nobel Prize in Physiology or Medicine 2018 for the discovery
of cancer therapy by inhibition of negative immune regulation
(Wolchok, 2018).
PD-1 interacts with the ligands PD-L1 (CD274; also called B7-
H1) and PD-L2 (CD273; also called B7-DC), which show distinct
expression patterns. In vitro, PD-1 inhibits T cell activation by
recruiting Src homology region 2-containing protein tyrosine
phosphatase 2 (SHP2) after interaction with its ligands on APCs
(Chen and Flies, 2013; Okazaki et al., 2013; Sharpe and Pauken,
2018). This is associated with dephopshorylation of crucial
tyrosine residues within the CD3 complex and CD28. In virus-
infected mice lacking SHP2 in T cells, however, PD-1 signaling
is not impaired, suggesting the existence of redundant inhibitory
pathways downstream of PD-1 (Rota et al., 2018).
PD-L1 is expressed not only by all hematopoietic cells
but also by many non-hematopoietic cell types such as
endothelial cells and epithelial cells (Sharpe and Pauken, 2018).
In contrast, PD-L2 expression is more restricted and can be
induced on hematopoietic cells such as DCs, B cells, and
monocytes/macrophages. Besides PD-1, there are other known
interacting partners for PD-L1 and PD-L2. PD-L1 also binds
to CD80 whereas PD-L2 uses RGM domain family member
B (RGMB) as an alternative binding partner. Both types of
interaction also inhibit immune responses (Butte et al., 2007;
Xiao et al., 2014).
Viruses have to overcome strong barriers to replicate in the
hostile environment of their hosts (Virgin et al., 2009). An arsenal
of weapons helps viruses to subvert antiviral immunity. This
includes the exploitation of host inhibitory receptor signaling
pathways (Ong et al., 2016). The impact of the PD-1/PD-L1
axis in chronic virus infections is well described whereas its role
during the acute phase of viral infections is less clear (Brown et al.,
2010; Attanasio and Wherry, 2016). However, whether virus-
induced upregulation of PD-1 ligands represents a viral immune
evasion strategy or an adaption of the host defense to minimize
immunopathology is a moot point. In this review, we highlight
the diverse roles of PD-1 and its ligands during virus infections
and their implications for host-pathogen interaction.
THE ROLE OF THE PD-1 PATHWAY IN
ACUTE VIRUS INFECTIONS
In mice acutely infected with lymphocytic choriomeningitis
virus (LCMV) strain Armstrong (LCMV Arm) PD-1 is rapidly
upregulated on naïve virus-specific CD8+ T cells before they
clonally expand (Ahn et al., 2018). In this model of acute LCMV
infection, CD4+ T cells are not required for virus clearance,
which occurs within 1–2 weeks after infection (Matloubian
et al., 1994). Blockade of the PD-1 pathway at this stage further
increases effector functions of CD8+ T cells by enhancing
granzyme B expression and mechanistic Target of Rapamycin
(mTOR) signaling. Consequently, virus elimination is accelerated
although the total number of virus-specific CD8+ T cells
does not change (Ahn et al., 2018). Similarly, the PD-1/PD-L
axis inhibits the differentiation of CD8+ T lymphocytes into
polyfunctional cytotoxic T cells during acute infection of mice
with murine retrovirus (David et al., 2019). This implies that
PD-1 negatively regulates the terminal differentiation of naïve
CD8+ T cells into effector CD8+ T lymphocytes during acute
virus infection.
After virus clearance, PD-1 expression on virus-specific T cells
returns to normal levels (Barber et al., 2006; Blattman et al., 2009).
The expanded pool of virus-specific effector T lymphocytes
contracts due to increased cell death and memory T cells arise
from a subset of fate-permissive effector T cells (Akondy et al.,
2017; Omilusik and Goldrath, 2017; Youngblood et al., 2017).
There are at least three major memory T cell subsets: central
memory T cells (Tcm cells), effector memory T cells (Tem cells),
and recently defined tissue-resident memory T cells (Trm cells).
Tcm cells lack effector functions but express lymph node homing
molecules and circulate through the blood and the secondary
lymphoid organs (Sallusto et al., 1999). After stimulation, Tcm
cells differentiate into Tem cells that lack lymph node homing
molecules and continuously recirculate between blood, lymph
and non-lymphoid tissues. Tem cells are bestowed with various
effector functions (Sallusto et al., 1999). In contrast, Trm cells
do not recirculate (Wakim et al., 2008; Gebhardt et al., 2009;
Masopust et al., 2010) and express core phenotypic markers
including co-inhibitory receptors such as PD-1 (Hombrink et al.,
2016; Kumar et al., 2017; Pallett et al., 2017). Functionally,
Trm cells participate in the first line of defense to viruses by
establishing an antiviral state and recruiting circulating memory
T cells to sites of viral infection (Schenkel et al., 2013, 2014;
Ariotti et al., 2014; Carbone and Gebhardt, 2014). Located in
multiple anatomical sites including barrier tissue such as lung,
skin and gut, Trm cells are indispensable for antiviral immunity
and immunosurveillance (Shin, 2018;Wu et al., 2018; Szabo et al.,
2019). The functional role of the PD-1/PD-L1 axis for CD8+Trm
cells is unclear at the moment but it may prevent uncontrolled
Trm activation and inflammation in virus-infected tissues and
other inflammatory conditions. In accordance, blockade of PD-
1 on Trm cells increases the severity of eczema in a mouse model
of allergic contact dermatitis (Gamradt et al., 2019).
Intriguingly, the number of memory precursor T cells
increases if PD-1 is blocked by antibodies during acute LCMV
infection, possibly due to faster virus elimination (Ahn et al.,
2018). Virus-specific memory CD8+ T cells that develop after
the elimination of LCMV persist without antigen and are capable
of self-renewal due to homeostatic proliferation in response
to IL-7 and IL-15 (Wherry et al., 2004; Surh and Sprent,
2008; Abdelsamed et al., 2017). Although the blockade of the
PD-1/PD-L1 axis in mice infected with LCMV Arm increases
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effector CD8+ T cell function, no excessive tissue damage is
observed (Ahn et al., 2018). Similar to the LCMV strain WE
(LCMV WE), LCMV Arm does not disseminate but instead is
eliminated from infected laboratory mice after acute infection. In
contrast, derivatives of LCMV Arm and LCMV WE (“clone 13”
and “docile,” respectively) replicate more vigorously and persist
(Matloubian et al., 1990; Welsh and Seedhom, 2008). These
LCMV strains cause lethal immunopathology in mice deficient
of the PD-1/PD-L1 axis (PD-L1 KOmice, PD-1 KOmice) during
the acute phase of infection (Barber et al., 2006; Mueller et al.,
2010; Frebel et al., 2012; Zinselmeyer et al., 2013; Shaabani et al.,
2016). This is due to the killing of LCMV-infected vascular
endothelium by CD8+ T cells resulting in vascular leakage with
pulmonary edema and severe hypotension (Frebel et al., 2012).
In a mouse model of acute viral hepatitis, the absence of PD-1 is
associated not only with more rapid virus clearance but also with
more severe hepatitis (Iwai et al., 2003). These results imply that
the stimulation of the PD-1/PD-L1 axis during the acute phase
of virus infection helps to adjust the strength and quality of the
cytotoxic CD8+ T cell attack so that the good (virus elimination)
and the bad (tissue damage) is balanced, preventing excessive
tissue damage.
VIRUS-DRIVEN PD-L1/2 EXPRESSION
Many viruses increase PD-L1/2 expression on hematopoietic
cells (Table 1) and non-hematopoietic cells (Table 2). PD-
L1/2 expression is regulated by proinflammatory and anti-
inflammatory signals (Sun et al., 2018). The promotor regions
of PD-L1 and PD-L2, which are paralog genes, are differentially
regulated although they show similarly arranged binding sites for
transcription factors (Garcia-Diaz et al., 2017).
Type I and type III interferons (IFNs) are important antiviral
cytokines. They are induced early in virus-infected barrier tissue
such as lung/gut epithelial cells and serve as the first line of
antiviral defense (Okabayashi et al., 2011; Wack et al., 2015;
Andreakos et al., 2017; Galani et al., 2017; Zanoni et al., 2017;
Good et al., 2019; Lazear et al., 2019). Type I IFNs, which in
humans include several IFN-α subtypes and IFN-β, increase
PD-L1 expression but to a lesser extent than PD-L2 expression
(Garcia-Diaz et al., 2017). PD-L2 responds equally well to IFN-
γ (type II IFN) and IFN-β (Garcia-Diaz et al., 2017). IL-4 may
be an even more potent inducer of PD-L2 (Loke and Allison,
2003) thus accounting for the presence of PD-L2 on monocyte-
derived DCs generated in vitro. Blockade or absence of type I
IFN signaling during chronic LCMV infection results in reduced
PD-L1 expression despite enhanced viral replication (Teijaro
et al., 2013; Wilson et al., 2013; Shaabani et al., 2016). Although
type I IFNs moderately upregulate PD-L1 (Sun et al., 2018)
they increase NK cytotoxicity and allow clonal expansion and
memory formation of antiviral cytotoxic CD8+ T cells (Biron
et al., 2002; Kolumam et al., 2005; Aichele et al., 2006). Type III
IFNs signal through a unique heterodimeric receptor and induce
the expression of antiviral IFN-stimulated genes (ISGs) similar
to type I IFNs (Davidson et al., 2015). Intriguingly, type III IFNs
do not upregulate PD-L1 (Raftery et al., 2018). Accordingly, in
this early phase of acute infection the PD-1/PD-L1 axis does not
inhibit antiviral immune cells.
Recognition of viruses by pattern recognition receptors
(PRRs) also upregulates PD-L1. TLR3 signaling in particular
strongly increases PD-L1 levels on DCs (Pulko et al., 2009;
Boes and Meyer-Wentrup, 2015; Raftery et al., 2018) whereas
RIG-I signaling alone has no significant effect (Raftery et al.,
2018). Triggering of TLR3, which transmits downstream signals
through the TIR-domain-containing adapter-inducing IFN-β
(TRIF), also enhances PD-L1 on other cell types including
endothelial cells (Cole et al., 2011) and epithelial cells (Tsuda
et al., 2005). In accordance, virus-induced PD-L1 upregulation
on neuronal cells is severely impaired in TLR3-deficient mice
(Lafon et al., 2008). Recently, viral proteins inducing PD-L1/PD-
L2 expression have been identified. For example, HIV Tat protein
increases PD-L1 expression on DCs through TNF-α and TLR4
signaling (Planes et al., 2014). The HCV core protein in vitro
induces strong PD-L1 upregulation on primary human Kupffer
cells andmonocytes in a TLR2- and PI3K-dependentmanner (Tu
et al., 2010; Zhai et al., 2017). In accordance, the PD-L1 levels on
monocytes from HCV-infected patients were significantly higher
than onmonocytes from healthy individuals (Zhai et al., 2017). A
recent study has shown that extracellular vesicles (EVs) produced
by HBV-infected hepatocytes are endocytosed by circulating
monocytes resulting in PD-L1 upregulation (Huang et al.,
2017; Kakizaki et al., 2018). Moreover, PD-L1 and PD-L2 are
upregulated by hantaviral N protein most likely via hantavirus-
induced TLR3 signaling (Raftery et al., 2018). In addition, the
latency-associated transcripts (LATs) of herpes simplex virus type
1 (HSV-1) upregulate PD-L1 on mouse neuroblastoma cells by
an unknown mechanism (Chentoufi et al., 2011). Remarkably, as
of yet no viral immunoevasin has been discovered that directly
interacts with the molecules of the PD-1/PD-L1 axis to exploit its
immunosuppressive function.
Viral replication can also result in the production of anti-
inflammatory cytokines such as IL-10 (Brooks et al., 2006b;
Ejrnaes et al., 2006). Cellular IL-10 has been shown to upregulate
the expression of PD-1 and PD-L1 in a STAT-3 dependent
manner in DCs and monocytes (Curiel et al., 2003; Selenko-
Gebauer et al., 2003; Sun et al., 2015; Lamichhane et al.,
2017). Accordingly, the absence of cellular IL-10 in LCMV
infected mice results in enhanced effector T cell responses,
rapid virus elimination, and generation of antiviral memory T
cells (Brooks et al., 2006b; Ejrnaes et al., 2006). Intriguingly,
during coevolution with their hosts members of the virus
family Herpesviridae have acquired numerous genes from their
hosts including those that mimic cellular IL-10 (Raftery et al.,
2000; Ouyang et al., 2014; Schonrich et al., 2017). These viral
IL-10 (vIL-10) molecules act as immunosuppressive cytokines
that also paralyze co-stimulatory B7 molecules (Muller et al.,
1998; Raftery et al., 2004). It is possible that vIL-10 molecules
also increase signaling through the PD-1/PD-L1 axis similar
to their cellular counterparts thereby contributing to viral
persistence. However, combined blockade of both, IL-10 and PD-
L1, during chronic LCMV infection enhances T-cell function
more efficiently than a single blockade (Brooks et al., 2008).
Thus, IL-10 is pleiotropic and has immunosuppressive functions
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TABLE 1 | Virus-induced upregulation of PD-1 ligands on hematopoietic cells.
Virus Findings References
LCMV Arm and clone13 Increased PD-L1 expression on myeloid DCs and marginal zone macrophages;
decreased T cell motility in the marginal zone of the spleen due to PD-L1
Zinselmeyer et al., 2013
LCMV High PD-L1 expression on Kupffer cells in the liver Shaabani et al., 2016
IAV Type I IFN induced PD-L1 expression on virus-infected professional APCs in the
airways
Erickson et al., 2012; Valero-Pacheco et al., 2013;
Rutigliano et al., 2014; Staples et al., 2015;
McKendry et al., 2016
JEV PD-L1 upregulation on virus-infected DCs in vitro and decreased expansion of
Treg cells by virus-infected DCs after PD-L1 blockade
Gupta et al., 2014
EOBV Increased numbers of PD-L1 transcripts during EOBV infection of monocytes
derived from macaques
Menicucci et al., 2017
HV PD-L1/2 upregulation on DCs; high amounts of soluble PD-1 and PD-L2 in the
circulation of HV-infected patients
Raftery et al., 2018
FV PD-L1 expression on erythroid precursor cells and CD4+ T lymphocytes Akhmetzyanova et al., 2015
HIV PD-L1/2 upregulation on monocytes, DCs and macrophages; Correlation
between level of PD-L1 expression and disease progression
Boasso et al., 2008; Meier et al., 2008; Wang et al.,
2008; Rodriguez-Garcia et al., 2011
SIV Upregulation of PD-L1 on DCs; correlation between level of PD-L1 expression
and disease progression; improved function of antiviral T cells function after
PD-L1 blockade
Xu et al., 2010
HSV-1 Increased PD-L1 expression on DCs in the draining lymph nodes after virus
inoculation into foot pads of mice
Channappanavar et al., 2012
VZV PD-L1/2 upregulation on human monocytes, B cells, NK cells, and NKT cells Jones et al., 2019
KSHV Increased PD-L1 expression on monocytes Host et al., 2017
Ad, adenovirus; EOBV, Ebola virus; FV, Friend retrovirus; HIV, human immunodeficiency virus; HSV-1, herpes simplex virus type 1; HV, hantavirus; IAV, Influenza A virus; JEV, Japanese
encephalitis virus; KSHV, Kaposi’s sarcoma-associated herpesvirus; LCMV, lymphocytic choriomeningitis virus; LCMV Arm, LCMV strain Armstrong; LCMV clone13, LCMV strain
clone13; RSV, respiratory syncytial virus; Treg cells, regulatory T cells; VZV, varicella zoster virus.
TABLE 2 | Virus-induced PD-L1 upregulation on non-hematopoietic cells.
Viruses Findings References
LCMV PD-L1 upregulation on fibroblastic reticular cells Zinselmeyer et al., 2013
Ad Increased PD-L1 expression on primary human hepatocytes Grakoui et al., 2006; Muhlbauer et al., 2006
HBV Upregulated PD-L1 expression on hepatocytes derived from a transgenic mouse
model of BV infection
Maier et al., 2007
IAV, MHPV, PIV-3, RSV Increased levels of PD-L1 on alveolar and bronchiolar epithelial cells after virus
infection in vitro and in patients with viral acute lower tract infections
Stanciu et al., 2006; Telcian et al., 2011; Erickson
et al., 2012; McNally et al., 2013
RABV Type I IFN-dependent PD-L1 upregulation on virus-infected mouse and human
neuronal cells in vitro and on neuronal cells in virus-infected mice
Lafon et al., 2008
HSV-1 PD-L1 upregulation on mouse neuroblastoma cells Chentoufi et al., 2011
HSV-1 PD-L1 upregulation on virus-infected neurons in ganglia Jeon et al., 2013
HSV-1 PD-L1 upregulation on epithelial cells in the virus-infected cornea Jeon et al., 2018
Ad, adenovirus; EOBV, Ebola virus; HMPV, human metapneumovirus; HBV, hepatitis B virus; HSV-1, herpes simplex virus type 1; HV, hantavirus; IAV, Influenza A virus; JEV, Japanese
encephalitis virus; LCMV, lymphocytic choriomeningitis virus; LCMV Arm, LCMV strain Armstrong; LCMV WE, LCMV strain WE; PIV-3, parainfluenza virus type 3; RABV, rabies virus;
RSV, respiratory syncytial virus; Treg cells, regulatory T cells; VHF, viral hemorrhagic fever.
independent of the PD-1/PD-L1 axis during persisting virus
infections (Ouyang et al., 2011).
In the late phase of acute virus infection, type II IFN
and several other cytokines including TNF-α and IL-10 are
released by immune cells such as CD8+ T cell cells (Zhang
and Bevan, 2011). IFN-γ strongly upregulates PD-L1 (Garcia-
Diaz et al., 2017; Raftery et al., 2018; Sun et al., 2018). In
addition, plasmacytoid DCs (pDCs) migrate into virus-infected
tissue and secrete large amounts of type I IFNs (Siegal et al.,
1999). These cytokines not only induce antiviral ISGs but also
drive inflammatory responses such as secretion of TNF-α, IL-1β,
or IL-6 (Davidson et al., 2015), which can further increase PD-
L1 on various cell types including endothelial cells and at the
same time promote non-lytic virus elimination (Sun et al., 2018).
Thus, in the late phase of acute viral infection, PD-L1 is strongly
upregulated thereby downregulating terminal differentiation of
CD8+ T cells and preventing excessive tissue damage due to
uncontrolled cytotoxic attack.
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FUNCTION OF PD-L1 DURING ACUTE
VIRUS INFECTIONS
PD-L1 expressed on hematopoietic or non-hematopoietic cells
has different functions (Keir et al., 2006; Mueller et al., 2010). For
example, PD-L1 expression on parenchymal cells of the pancreas
rather than hematopoietic cells prevent autoimmune diabetes
(Keir et al., 2006). In accordance, during LCMV infection of
mice PD-L1 expression on non-hematopoietic cells reduces
viral clearance and immunopathology (Keir et al., 2008). Thus,
upregulation of PD-L1 expression may protect virus-infected
cells from being eliminated by cytotoxic CD8+ T cells. On
the other hand, selective absence of PD-L1 on hematopoietic
cells results in lethal immunopathology (Mueller et al., 2010).
This is best explained by an increase in number and function
of cytotoxic CD8+ T lymphocytes, which may overwhelm
the PD-L1-conferred protection in non-hematopoietic target
cells (Frebel et al., 2012).
Virus-induced PD-L1 on professional APCs may help to focus
the antiviral CD8+ T cell response on a few strongly stimulatory,
i.e., immunodominant, virus-derived epitopes by increasing the
threshold of CD8+ T cell activation. In this way, the majority
of weakly immunogenic viral peptides fail to activate CD8+ T
cells. The adjustment of the “rheostat” on professional APCs
may be necessary to prevent autoimmune disease and maintain
peripheral tolerance in the face of a highly inflammatory milieu.
Indeed, a recent study has shown that the PD-L1/PD-1 axis
regulates T cell responses at the activation stage (Sugiura et al.,
2019). CD80, which binds to CD28 and CTLA-4 on T cells,
also interacts with PD-L1 (Butte et al., 2007, 2008). Importantly,
this interaction occurs only in cis (Chaudhri et al., 2018) and
prevents PD-L1 on DCs from co-inhibitory signaling to T
cells via PD-1 (Chaudhri et al., 2018; Sugiura et al., 2019). In
contrast, the functions of CD28 (co-stimulatory) and CTLA-4
(co-inhibitory) are not impaired by cis-PD-L1/CD80 interactions
on DCs (Sugiura et al., 2019). Many viruses upregulate PD-
L1 on professional APCs such as DCs (Table 1) either directly
or through IFN release. Low PD-L1 levels on uninfected DCs
have only a weak impact on T cell activation (Brown et al.,
2003) due to cis-PD-L1/CD80 interactions (Figure 1, upper
scheme). It is likely, that the high PD-L1 levels on DCs in
the context of viral infection will overwhelm the cis-binding
capacity of CD80 resulting in increased co-inhibitory signaling
via PD-1 (Figure 1, lower scheme). PD-L1 on professional APCs
also promotes the induction and maintenance of regulatory
T cells (Treg cells; Francisco et al., 2009). Treg cells help to
confine the antiviral defense and to prevent immunopathology
during virus infections (Veiga-Parga et al., 2013). Taken together,
viruses can reprogram DC function in antiviral immune
responses by tipping the balance between co-inhibitory and
co-stimulatory signals as shown for murine cytomegalovirus
(Loewendorf et al., 2004; Benedict et al., 2008) and vaccinia
virus (Kleinpeter et al., 2019).
Strong stimulation of the PD-1/PD-L1 does not prevent
immunopathology during viral hemorrhagic fever (VHF). VHF
is a designation for distinct but pathogenically similar zoonotic
diseases that are caused by several enveloped RNA viruses
including Ebola virus (EBOV), hantavirus, and dengue virus
(DENV) (Paessler and Walker, 2013). VHF viruses target
endothelial cells thereby causing vascular leakage (Zampieri
et al., 2007; Schonrich et al., 2008; Basler, 2017). In fact, type
III IFN and TNF-α, which upregulate PD-L1 on endothelial
cells, also mediate dysfunction of the endothelial barrier (Brett
et al., 1989; Koh et al., 2004). Virus-specific CD8+ T cells show
high levels of PD-1 on the surface during acute infection with
EBOV (McElroy et al., 2015). Moreover, fatal EBOV infection
is characterized by a high percentage of T cells expressing PD-
1 and other co-inhibitory receptors such as CTLA-4 (Ruibal
et al., 2016). Monocytes are susceptible to EBOV infection and
upregulate production of PD-L1 transcripts in response to EBOV
replication (Menicucci et al., 2017), whereas DENV-infected DCs
express higher levels of PD-L2 but reduced PD-L1 (Nightingale
et al., 2008). In patients with acute hantavirus infection large
amounts of soluble PD-L1/PD-L2 are found in the sera indicating
that these molecules are strongly upregulated in hantavirus-
infected cells in vivo (Raftery et al., 2018). In accordance, strongly
increased PD-L1 levels are detected after hantavirus infection
of immature DCs in vitro and in hantavirus-infected mice with
a humanized immune system (Raftery et al., 2018). In striking
contrast, CD8+ T cells do not upregulate PD-1 during acute
hantavirus infection (Lindgren et al., 2011).
Taken together, in the acute phase of viral infection virus-
specific T cells rapidly upregulate the co-inhibitory receptor PD-1
upon recognition of antigen. Simultaneously, viruses upregulate
PD-L1 on hematopoietic and non-hematopoietic cells directly
through PRR signaling or indirectly by inducing the release of
IFNs and other inflammatory cytokines. Ideally, a tailor-made
antiviral CD8+ T cell response eliminates viral pathogens with
minimal immunopathology (Figure 2). The antiviral immune
response during VHF, however, eliminates viruses at the cost
of vascular leakage. The dysregulation of the immune responses
could be due to variations in PD-L1 expression (e.g., timing,
cell type, or strength), imbalance between co-stimulatory vs.
co-inhibitory receptors (failure of “checks and balances”), or
altered usage of PD-L1 interaction partners (PD-1, CD80, and
possibly additional unknown partners). On the other hand
viruses can also manipulate the “checks and balances” of
the immune system in such a way that an effective antiviral
immune response is prevented helping the pathogen to persist in
the organism.
THE PD-1/PD-L1 AXIS DURING
PERSISTING VIRUS INFECTIONS
Chronic Virus Infection
Chronic infections with viruses such as hepatitis B virus,
hepatitis C virus (HCV), and human immunodeficiency
virus (HIV) represent major causes of chronic disease and
death worldwide (Ott et al., 2012; Schweitzer et al., 2015;
GBD 2015 HIV Collaborators, 2016; Stanaway et al., 2016).
During chronic infection virus particles are continuously
released from virus-infected cells and maintain a network
of immunosuppressive mechanisms that interfere with virus
elimination (Ng et al., 2013). Therefore, T cells enter a state called
T cell exhaustion.
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FIGURE 1 | PD-L1 mediated viral regulation of T cell activation. Upper graph: In the absence of viral infection mature dendritic cells (DCs) express relatively low levels
of PD-L1. Recognition of cognate antigen (Ag) bound to MHC class I molecules by T cell receptor (TCR) results in upregulation of PD-1 on T cells. DCs express
co-stimulatory molecules CD80 and CD86 allowing efficient co-stimulation of T cells via CD28. The PD-1/PD-L1 axis is not co-inhibitory due to restriction by
cis-PD-L1/CD80 interactions, and thus T cells are activated. Lower graph: In the context of viral infection DCs upregulate PD-L1 due to exposure to viral PAMPs and
high levels of type I IFN. The restricting cis-PD-L1/CD80 interactions are most likely overwhelmed by virus-induced PD-L1 resulting in PD-1 signaling and prevention of
T cell activation. The consequences of this for the generation of Tregs is as of yet unknown.
T Cell Exhaustion and Partial Restoration
of T Cell Function by Blockade of the
PD-1/PD-L1 Axis
The first evidence for T cell exhaustion was gathered in
paradigmatic experiments using LCMV-infected mice (Zehn
and Wherry, 2015; Kahan and Zajac, 2019). Derivatives of
LCMV Arm and LCMV WE (LCMV clone13 and LCMV
docile, respectively) vigorously replicate and disseminate in
mice thereby persisting for more than 100 days (Moskophidis
et al., 1993; Gallimore et al., 1998; Zajac et al., 1998). In this
model of chronic virus infection, CD4+ T cells are crucial to
sustain the virus-specific CD8+ T cell responses (Matloubian
et al., 1994). Sustained upregulation of PD-1 and other co-
inhibitory receptors such as 2B4, CTLA-4, and lymphocyte-
activation gene 3 (Lag3) has become the defining characteristic
of exhausted T (Tex) cells (Barber et al., 2006; Wherry et al.,
2007; Blackburn et al., 2009; Crawford et al., 2014). These
phenotypic changes are accompanied by a multistep loss of T cell
effector functions (Speiser et al., 2014; Kahan et al., 2015; Wherry
and Kurachi, 2015; McKinney and Smith, 2018). Dependent on
the strength of PD-1 signaling CD8+ T lymphocytes gradually
lose important effector functions (Wherry et al., 2003; Wei
et al., 2013). Some are lost early (such as cytotoxicity, IL-
2 production, and proliferation), whereas others (e.g., IFN-γ
production) are maintained for a longer time (Wherry et al.,
2003; Wei et al., 2013). Finally, Tex cells undergo apoptosis
(Kahan et al., 2015). As an underlying mechanism of T cell
exhaustion during chronic LCMV infection, PD-1 signaling
impairs T cell motility facilitating engagement of inhibitory
pathways in T cells (Zinselmeyer et al., 2013). In another
experimental setting, PD-L1 blocking antibodies prolong the
T cell migration arrest suggesting that PD-1 signaling in fact
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FIGURE 2 | The PD-1/PD-L1 checkpoint in acute virus infection. Early phase:
The infected tissue produces type I IFNs and possibly type III IFNs, which
strongly induce antiviral IFN-stimulated genes (ISGs) but only moderate PD-L1
levels. Antiviral CD8+ T cells eliminate virus-infected cells. At this stage, the
PD-1/PD-L1 checkpoint activity is low and does not restrict the antiviral
immune response. Late Phase: Type II IFN and TNF-α is secreted by CD8+ T
cells and other immune cells. In addition, hematopoietic cells such as
plasmacytoid DCs (pDCs) produce large amounts of type I IFN. This results
not only in virus elimination but also increases PD-L1 expression. The high
checkpoint activity downregulates terminal differentiation of antiviral CD8+ T
cells. Ideally, the strength and quality of the CD8+ T cell response is balanced
out in such a way that the viral intruder is eliminated without causing
immunopathology.
enhances T cell motility (Honda et al., 2014). The reason for
these contrasting results are unclear at the moment. Intriguingly,
PD-1-regulated changes in several metabolic pathways occur at
the very beginning of Tex cell development underlining the
importance of these metabolic processes in the execution of
the Tex program (Bengsch et al., 2016; Schurich et al., 2016;
McKinney and Smith, 2018).
Several reports have found differences in the transcriptional
program and epigenetic profile of Tex cells as compared to
memory and effector T lymphocytes (Wherry et al., 2007;
Doering et al., 2012; Pauken et al., 2016). In Tex cells derived
from LCMV-infected mice, the Pdcd1 regulatory region is
completely demethylated and remains so even when virus titers
decrease (Youngblood et al., 2011). They do not show antigen-
independent persistence driven by IL-7 and IL-15, the hallmark
of memory T cells, and instead require the continuous presence
of their cognate antigen (Wherry and Ahmed, 2004; Shin
et al., 2007). This can be explained by the observation that
the TCR-induced transcription factors IRF4, BATF, and NFATc1
not only drive T cell exhaustion but also impair memory T
cell development during chronic LCMV infection (Man et al.,
2017). Recently, microRNA (miR)-155 has been identified as a
key molecule that promotes long-term persistence of Tex cells
(Stelekati et al., 2018).
T cells that have been rendered dysfunctional during
persisting virus infections can be reinvigorated (Brooks et al.,
2006a). Blockade of the PD-1/PD-L1 axis during chronic LCMV
infection reinvigorates antiviral T cell functions and reduces viral
load (Barber et al., 2006). Of note, CD8+ T cells also become
exhausted in the absence of PD-1 (Odorizzi et al., 2015). These
experiments show that other coinhibitory receptors contribute to
T cell exhaustion. In line with this view, a combined blockade
of PD-1 and LAG-3 or PD-1 and Tim-3 synergistically improves
antiviral CD8+ T cell responses and viral control in mice with
chronic LCMV infection (Blackburn et al., 2009; Jin et al., 2010).
Reinvigorated CD8+ T cells in chronically LCMV-infected mice
become exhausted again after termination of the PD-L1 blockade
(Pauken et al., 2016; Sen et al., 2016; Turner and Russ, 2016). This
finding indicates that inflexibility of the epigenetic regulation in
Tex cells may limit the success of therapies using ICIs.
The studies of chronic LCMV infection in mice also relate to
important human infectious diseases. In a recently established
mouse model of HCV infection Tex cells are observed in
the liver of mice infected with a newly identified Norway rat
hepacivirus (NrHV), which belong to the same virus family as
HCV (Billerbeck et al., 2017; Klenerman and Barnes, 2017). In
NrHV-infected mice, CD4+ T cells were important to maintain
the antiviral CD8+ T cell response similar to the LCMV model
of chronic virus infection (Billerbeck et al., 2017). Blockade of
the PD-1/PD-L1 axis in early chronic infection reduced the
viral load whereas no beneficial effects were observed at later
time points (Billerbeck et al., 2017). Moreover, ICIs blocking
the PD-1 pathway can reinvigorate to some extent Tex cells
in humans chronically infected with HBV or HCV (McKinney
and Smith, 2016; Cox et al., 2017; Saeidi et al., 2018; Wykes
and Lewin, 2018). Targeting the PD-1/PD-L1 pathway during
retroviral infections has beneficial effects for virus control (Velu
et al., 2015). PD-1 upregulation is linked to a loss of function
in HIV-specific CD8+ T cells, which can be partially reversed
in vitro by a blockade of the PD-1/PD-L1 axis (Day et al., 2006;
Trautmann et al., 2006). Surprisingly, the context and timing of
PD-1 blockade seems to be important for its functional outcome:
PD-1 signaling inhibition during stimulation of naive CD8+ T
cells results in diminished activation, whereas PD-1 blockade
during the T cell effector phase increases activation (Garcia-Bates
et al., 2019). PD-1 blockade in rhesus macaques infected with
simian immunodeficiency (SIV) rapidly increases the number
and functional quality of virus-specific CD8+ T cells (Velu et al.,
2009). Intriguingly, the combination of anti-PD-1 antibodies and
antiretroviral therapy further improves antiviral CD8+ T cell
function in SIV-infected rhesus macaques (Mylvaganam et al.,
2018). This observation implies that directly acting antivirals
(DAAs) reducing the viral load and ICIs releasing the brake in
Tex cells synergistically increase antiviral T cell responses.
Recent data suggest that PD-1 expression does not necessarily
reflect T cell failure but rather adaption of T cell function to
chronic inflammation (Utzschneider et al., 2013, 2016; Speiser
et al., 2014; Staron et al., 2014; Zehn et al., 2016; Barnes, 2018;
Petrelli et al., 2018). In fact, at least two CD8+ Tex cell subsets
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exist that act in concert to mount a partially effective CD8+ T
cell response for control of chronic virus infection (Paley et al.,
2012). Moreover, Tex cells have the capacity for self-renewal and
are not entirely functionally inactive (Paley et al., 2012). The latter
finding implies that Tex cells may represent a form of antiviral
defense that is evolutionary adapted to the need to control a
chronically replicating non-lytic virus with minimal collateral
tissue damage and immunopathology. Moreover, experiments
in mice with genetic ablation of PD-1 suggest that PD-1 is not
required for induction of Tex cells (Odorizzi et al., 2015). In
fact, PD-1 may play a pivotal role in maintaining Tex cells
by preventing excessive stimulation that leads to proliferation
and terminal differentiation (Odorizzi et al., 2015). After the
elimination of HCV by DAAs, PD-1 expressing CD8+ T cell
populations remain that display characteristics of memory cells
including antigen-independent survival and proliferation after
re-challenge with antigen (Wieland et al., 2017).
Latent Infection and Reactivation
Viruses that establish latent infection include the members
of the family Herpesviridae. In contrast to chronic infection,
latent infection is characterized by periodic suspension of virus
replication. However, the blueprint of viral particles is preserved
in the latently infected host cells enabling the virus to reactivate
and resume virus production. It is a matter of debate whether
reactivation from latent virus infection creates enough antigenic
load to induce exhaustion of antiviral CD8+ T cells. Memory
CD8+ T cells recognizing viral antigens in the context of
chronic virus infections (e.g., HIV) more frequently express PD-
1 than memory CD8+ T cells stimulated by virus periodically
reactivating from latency, e.g., human cytomegalovirus (HCMV)
(Petrovas et al., 2006). This finding is consistent with the
idea that the amount of available antigen regulates PD-1
expression on reactive T cells (Petrovas et al., 2006). In
accordance, increased virus replication in immunosuppressed
patients with HCMV disease after allogeneic hematopoietic
cell transplantation is associated with PD-1 upregulation on T
cells (Gallez-Hawkins et al., 2009). In mice with a humanized
immune system, HCMV reactivations induced by granulocyte-
colony stimulating factor (G-CSF) resulted in a shift toward
PD-1 expressing T cells (Theobald et al., 2018). Whether
this phenotype corresponds to Tex cells is unclear, however.
Upregulation of co-inhibitory receptors such as PD-1 on CD8+
T cells is tightly linked to activation and differentiation and
not per se proof of T cell exhaustion (Legat et al., 2013).
In addition, studies of HSV-1 infection in mice did not
reveal evidence for functional impairment of virus-specific
CD8+ T cells during latency and subsequent reactivations
(Mackay et al., 2012).
PD-1 expression on brain Trm cells is maintained
independently from antigen (Shwetank et al., 2017). Recently,
it has been shown that Trm cells provide immunosurveillance
in the human brain to eliminate neurotropic viruses (Smolders
et al., 2018). In accordance, reactivation of HSV-1 from latently
infected neurons of the mouse is controlled by CD8+ Trm
lymphocytes (Liu et al., 2000; Khanna et al., 2003; Verjans et al.,
2007). These immune cells provide IFN-γ which upregulates
PD-L1 on HSV-1-infected neurons (Jeon et al., 2013). CD8+
T cells recognizing subdominant epitopes derived from HSV-1
proteins other than glycoprotein B (gB) but not CD8+ T cells
specific for the dominant gB-derived epitope show a partial
exhausted phenotype with increased PD-1 expression (Jeon
et al., 2013). Blockade of PD-L1 resulted in increased survival
of exhausted CD8+ T cells that were non-functional and not
protective, however (Jeon et al., 2013). In contrast, it has been
reported that HSV-1 LATs promotes functional exhaustion of
CD8+ T cells specific for the dominant gB-derived epitope
(Allen et al., 2011; Chentoufi et al., 2011).
During coevolution with their host, herpesviruses developed
numerous mechanisms to evade the antiviral immune response
such as modulation of programmed cell death (Raftery et al.,
1999, 2001; Muller et al., 2004; Kather et al., 2010) and
downregulation of MHC class I molecules (Schuren et al.,
2016). Intriguingly, replication competent varicella-zoster virus
(VZV) downregulates MHC class I and PD-L1 molecules in
human brain vascular adventitial fibroblasts, perineurial cells,
and human lung fibroblasts (Jones et al., 2016). In contrast, VZV
upregulates PD-L1 in hematopoietic cells (Jones et al., 2019).
The mechanism underlying VZV-associated downregulation of
PD-L1 is posttranscriptional in nature but the VZV-encoded
protein responsible has not yet been identified (Jones et al.,
2016). VZV might target PD-L1 to increase the migration
arrest of T cells (Honda et al., 2014). In this way, the virus
could more efficiently spread from lung fibroblasts to T cells,
which play crucial role in VZV dissemination to the skin
(Arvin et al., 2010).
CONCLUDING REMARKS
It is a seductive proposition that a virus induces PD-1 ligands in
order to inhibit and thus evade the host immune response. On the
other hand, recent data on the regulation of PD-L1 expression
during viral infection suggest that PD-L1 upregulation is rather
a part of the normal innate response induced by IFNs and PRR
signaling. The reason for this is still enigmatic. PD-L1 may have
a yet not defined immunostimulatory role in the very early phase
of viral infection. Later, it may adjust the quantity and quality
of the antiviral CD8+ T cell response in such a way that virus
is eliminated with minimal collateral tissue damage. The PD-
1/PD-L1 axis may also be important to maintain antiviral Trm
cells and Tex cells. Virus-induced PD-1 ligand expression as an
immune evasion strategy should always be rigorously tested with
this in mind.
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